CG Oncology (CGON) Net Income (2023 - 2026)
CG Oncology's (CGON) quarterly Net Income came in at -$443.0 million in Q1 2026, down 263.8% YoY from $270.4 million in Q1 2025, and down 981.1% on a QoQ basis from -$41.0 million in Q4 2025.
CG Oncology (CGON) Net Income (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Net Income data on file, last reported at -$443.0 million in Q1 2026.
- Quarterly Net Income fell 263.8% year-over-year to -$443.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$866.6 million (down 72.23% YoY) and the FY2025 annual result came in at -$359.4 million, down 83.18% from the prior year.
- Net Income retreated to -$443.0 million in Q1 2026, from -$41.0 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$8.9 million in Q1 2023 to a low of -$443.0 million in Q1 2026.
- A 4-year average of -$128.2 million and a median of -$121.8 million in 2025 frame the typical range for Net Income.
- Annual changes were most pronounced in 2024 — Net Income tumbled 2673.52% — and 2025, when it jumped 50.92%.
- Tracing CGON's Net Income over 4 years: stood at -$16.6 million in 2023, then tumbled by 92.52% to -$31.9 million in 2024, then dropped by 28.6% to -$41.0 million in 2025, then plunged by 981.1% to -$443.0 million in 2026.
- The last three Net Income figures came in at -$443.0 million (Q1 2026), -$41.0 million (Q4 2025), and -$234.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -465.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -465.70 Mn |
| Mar 31, 2026 | -442.99 Mn |
| Dec 31, 2025 | -40.98 Mn |
| Sep 30, 2025 | -234.43 Mn |
| Jun 30, 2025 | -148.18 Mn |
| Mar 31, 2025 | -121.77 Mn |
| Dec 31, 2024 | -31.86 Mn |
| Sep 30, 2024 | -177.59 Mn |
| Jun 30, 2024 | -171.94 Mn |
| Mar 31, 2024 | -248.12 Mn |
| Dec 31, 2023 | -16.55 Mn |
| Sep 30, 2023 | -11.82 Mn |
| Jun 30, 2023 | -11.60 Mn |
| Mar 31, 2023 | -8.95 Mn |